KLF2 and lymphoma: From a prognostic standpoint,KLF2 mutations andNOTCH2 mutations represent promising prognostic biomarkers associated with poor survival and transformation to aggressive lymphoma whose broad application in clinical practice requires the assessment of whether their incorporation into the currently available clinical prognostic models improves risk stratification of patients.